Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)

INTRODUCTION: Osimertinib is an effective therapy in EGFR mutant NSCLC, but resistance invariably develops. Navitoclax is an oral inhibitor of BCL-2/BCL-xL that has exhibited synergy with osimertinib in preclinical models of EGFR-mutant NSCLC. In hematologic malignancies, BCL-2 family inhibitors in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Bertino, Erin M., Gentzler, Ryan D., Clifford, Sarah, Kolesar, Jill, Muzikansky, Alona, Haura, Eric B., Piotrowska, Zofia, Camidge, D. Ross, Stinchcombe, Thomas E., Hann, Christine, Malhotra, Jyoti, Villaruz, Liza C., Paweletz, Cloud P., Lau, Christie L., Sholl, Lynette, Takebe, Naoko, Moscow, Jeffrey A., Shapiro, Geoffrey I., Jänne, Pasi A., Oxnard, Geoffrey R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7976451/
https://ncbi.nlm.nih.gov/pubmed/33376097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4084
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados